Pupljenje tumora u tumorskom tkivu kod bolesnika operisanih zbog adenokarcinoma pluća
Sažetak
Uvod/Cilj. Fenomen tumorskog pupljenja sve više biva prepoznat kao značajna determinanta progresije i loše prognoze različitih tipova karcinoma. Cilj studije je bila kliničko-patološka evaluacija ovog fenomena u adenokarcinomu pluća. Metode. Studija je obuhvatila 114 bolesnika operisanih od adenokarcinoma pluća u periodu od jedne godine. Prisustvo i gustina tumorskih pupoljaka analizirani su mikroskopski. Dobijeni rezultati su upoređivani u odnosu na pol i starost bolesnika, veličinu primarnog tumora, nodalni status i stadijum bolesti. Rezultati. U grupi bolesnika sa potvrđenim prisustvom tumorskog pupljenja bilo je 34 (55,7%) muškaraca i 27 (44,3%) žena, a u grupi bez prisustva tumorskog pupljenja 30 (56,6%) muškaraca i 23 (43,4%) žena. Nije uočena statistički značajna razlika u starosnoj dobi između muškog (64,3 ± 6,59 godina) i ženskog pola (63,1 ± 6,53 godina) kod bolesnika sa prisustvom tumorskih pupoljaka u tumorskom tkivu, kao ni kod muškog (63,3 ± 6,02 godina) i ženskog pola (63,2 ± 6,72 godina) kod bolesnika bez tog prisustva. Primarni tumor bio je značajno veći (p < 0.05) kod bolesnica sa fenomenom tumorskog pupljenja. U grupi bolesnika u čijem je tumorskom tkivu dokazan fenomen pupljenja dominirao je nodalni stadijum N1 (p < 0,05) i stadijum III bolesti (p < 0,05). Zaključak. Sa potvrđenom statističkom značajnošću između višeg nodalnog statusa, stadijuma bolesti i tumorskog pupljenja, pokazano je da ovaj fenomen, iako relativno nov u dijagnostičkom domenu patologije, privlači dodatnu pažnju kao značajan prognostički faktor. Dobijeni rezultati bi mogli pomoći u integrisanju ovog fenomena u postojeće skoring sisteme kao dodatka ostalim prediktorima koji ukazuju na lošiju prognozu bolesti.
Reference
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277‒300.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64(1): 9‒29.
Kerr KM. Personalized medicine for lung cancer: new challeng-es for pathology. Histopathology 2012; 60(4): 531–46.
Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of pa-tients with lung adenocarcinoma. Nat Med 2002; 8(8): 816–24.
Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009; 10: 1001–10.
Šolajić N. Prognostic significance of density of tumor buds and cytoplasmic pseudofragments in stage II colonic carcinoma [dissertation]. Novi Sad: Faculty of Medicine, University of Novi Sad; 2016. (Serbian)
Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest 2009; 119(6): 1420–8.
Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of chang-ing cell state in development and disease. J Clin Invest 2009; 119(6): 1438‒49.
Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as on-cotarget. Oncotarget 2010; 1(7): 651‒61.
Kalluri R. EMT: when epithelial cells decide to become mes-enchymal- like cells. J Clin Invest 2009; 119(6): 1417‒9.
Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer—ready for diagnostic practice? Human Pathology 2016; 47(1): 4‒19.
Dawson H, Lugli A. Molecular and pathogenetic aspects of tu-mor budding in colorectal cancer. Front Med (Lausanne) 2015; 2: 11.
Masuda R, Kijima H, Imamura N, Aruga N, Nakamura Y, Masu-da D, et al. Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients. Mol Med Rep 2012; 6(5): 937‒43.
Gabbert H, Wagner R, Moll R, Gerharz CD. Tumor dedifferen-tiation: an important step in tumor invasion. Clin Exp Metas-tasis 1985; 3(4): 257–79.
Prall F. Tumour budding in colorectal adenocarcinoma. His-topathology 2007; 50(1): 151‒62.
Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour “budding” as an index to estimate the potential of aggressive-ness in rectal cancer. Histopathology 2002; 40(2): 127‒32.
Sy J, Fung CL, Dent OF, Chapius PH, Bokey L, Chan C. Tumor budding and survival after potentially curative resection of node- positive colon cancer. Dis Colon Rectum 2010; 53(3): 301‒7.
Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Modern Patholo-gy 2012; 25(10): 1315‒25.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Clas-sification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. J Thorac Oncol 2015; 10(9): 1243–60.
Eguchi T, Kadota K, Park BJ, Travis WD, Jones DR, Adusumilli PS, et al. The New IASLC/ATS/ERS Lung Adenocarcinoma Classification: what the surgeon should know. Semin Thorac Cardiovasc 2014; 26(3): 210‒22.
Imai T. The growth of human carcinoma: a morphological analysis. Fukuoka Igaku Zasshi 1954; 45: 72‒102.
Grigore AD, Jolly MK, Jia D, Farach-Carson MC, Levine H. Tu-mor Budding: The Name is EMT. Partial EMT. J Clin Med 2016; 5(5): pii: E51.
Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or mod-erately differentiated colon adenocarcinoma. Dis Colon Rec-tum 2003; 46(10): 1400‒6.
Guzinska-Ustymowicz K. The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anti-cancer Res 2005; 25(2B): 1269‒72.
Prall F, Nizze H, Barten M. Tumour budding as prognostic fac-tor in stage I/II colorectal carcinoma. Histopathology 2005; 47(1): 17–24.
Zlobec I, Hädrich M, Dawson H, Koelzer VH, Borner M, Mallaev M, et al. Intratumoural budding (ITB) in preoperative biop-sies predicts the presence of lymph node and distant metasta-ses in colon and rectal cancer patients. Br J Cancer 2014; 110(4): 1008‒13.
Koelzer VH, Zlobec I, Berger MD, Cathomas G, Dawson G, Dirschmid K, et al. Tumor budding in colorectal cancer revisit-ed: Results of a multicenter interobserver study. Virchows Arch 2015; 466(5): 485–93.
Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 1993; 36(7): 627–35.
Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of me-tastasis to the lung and liver after curative excision of colorec-tal cancer. Hepatogastroenterology 2005; 52(65): 1432‒5.
Wang LM, Kevans D, Mulcahy H, O’Sullivan J, Fennelly D, Hy-land J, et al. Tumor budding is a strong and reproducible prog-nostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009; 33(1): 134–41.
Kadota K, Yeh Y, Villena-Vargas J, Cherkassky L, Drill EN, Si-ma CS, et al. Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma. Chest 2015; 148(3): 711‒21.
Yu K, Zhang C, Berry GJ, Altman RB, Re C, Rubin DL, et al. Predicting non-small cell lung cancer prognosis by fully auto-mated microscopic pathology image features. Nat Commun 2016; 7: 12474.
Yamaguchi Y, Ishii G, Kojima M, Yoh K, Otsuka H, Otaki Y, et al. Histopathologic Features of the Tumor Budding in Adeno-carcinoma of the Lung. Tumor Budding As an Index to Pre-dict the Potential Aggressiveness. J Thorac Oncol 2010; 5: 1361‒8.
Wang C, Huang H, Huang Z, Wang A, Chen X, Huang L, et al. Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J Oral Pathol Med 2011; 40(7): 545–51.
O’Connor K, Li-Chang HH, Kalloger SE, Peixoto RD, Webber DL, Owen DA, et al. Tumor budding is an independent ad-verse prognostic factor in pancreatic ductal adenocarcinoma. Am J Surg Pathol 2015; 39(4): 472–8.
Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Lykoudis P, Mellou A, et al. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer 2013; 49(5): 1032‒9.
Salhia B, Trippel M, Pfaltz K, Cihoric N, Grogg A, Lädrach C, et al. High tumor budding stratifies breast cancer with metastatic properties. Breast Cancer Res Treat 2015; 150(2): 363‒71.
Almangush A, Salo T, Hagström J, Leivo I. Tumour budding in head and neck squamous cell carcinoma - a systematic review. Histopathology 2014; 65(5): 587‒94.
Manjula BV, Augustine S, Selvam S, Mohan AM. Prognostic and predictive factors in gingivo buccal complex squamous cell carcinoma: role of tumor budding and pattern of invasion. In-dian J Otolaryngol Head Neck Surg 2015; 67(1): 98–104.